Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

Stephen J. Freedland, MD
Published: Tuesday, Feb 18, 2020



Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of surgery, Cedars-Sinai Medical Center, discusses a real-world analysis of enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Data from the randomized phase III PREVAIL trial showed a decrease in radiographic progression-free survival and overall survival with enzalutamide versus placebo in men with chemotherapy-naïve, metastatic prostate cancer.

Prior to the 2018 approval of enzalutamide in nonmetastatic CRPC, a retrospective cohort study analyzed the real-world utility of enzalutamide in 931 men with chemotherapy-naïve, mCRPC. Due to the agent’s approval in the nonmetastatic setting in the study time frame, the use of enzalutamide was used as a proxy for mCRPC, says Freedland.

At a median follow-up of 12.5 months and a median of 4 completed prostate-specific antigen (PSA) tests, the median PSA decline was 58%, says Freedland. Moreover, 14.2% of patients had undetectable PSA. Additionally, the median time to PSA progression was 18.5 months (95% CI, 15.6-23.7).

A subset of patients did not respond to treatment with enzalutamide; however, this may be due to inherent resistance to hormonal therapy, explains Freedland.

These findings are comparable to those from the PREVAIL trial, indicating the real-world utility of enzalutamide in this patient population, concludes Freedland.
SELECTED
LANGUAGE


Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of surgery, Cedars-Sinai Medical Center, discusses a real-world analysis of enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Data from the randomized phase III PREVAIL trial showed a decrease in radiographic progression-free survival and overall survival with enzalutamide versus placebo in men with chemotherapy-naïve, metastatic prostate cancer.

Prior to the 2018 approval of enzalutamide in nonmetastatic CRPC, a retrospective cohort study analyzed the real-world utility of enzalutamide in 931 men with chemotherapy-naïve, mCRPC. Due to the agent’s approval in the nonmetastatic setting in the study time frame, the use of enzalutamide was used as a proxy for mCRPC, says Freedland.

At a median follow-up of 12.5 months and a median of 4 completed prostate-specific antigen (PSA) tests, the median PSA decline was 58%, says Freedland. Moreover, 14.2% of patients had undetectable PSA. Additionally, the median time to PSA progression was 18.5 months (95% CI, 15.6-23.7).

A subset of patients did not respond to treatment with enzalutamide; however, this may be due to inherent resistance to hormonal therapy, explains Freedland.

These findings are comparable to those from the PREVAIL trial, indicating the real-world utility of enzalutamide in this patient population, concludes Freedland.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x